Tumor Gene Mutation Testing: Mainstream Technical Approaches and Key Points for Platform Selection

Introduction: Why standardized tumor gene mutation testing is needed

Tumor gene mutation testing analyzes specific genetic alterations in tumor cells or cell-free nucleic acids to provide reference information for tumor molecular classification, targeted drug selection, and prognostic assessment. With the development of molecular biology technologies, testing methods have gradually expanded from single-gene analysis to multigene parallel analysis, and both clinical and laboratory settings need to pay attention to methodological characteristics and applicable scope.

Common technical pathways for testing

At present, tumor gene mutation testing mainly includes the following categories of technologies:

Polymerase chain reaction (PCR)-based technologies: primers or probes are designed for known hotspot mutations, with relatively simple operation and short turnaround time, suitable for detecting common mutation sites.

High-throughput sequencing (NGS): can simultaneously analyze multiple types of variants across multiple genes, including point mutations, insertions and deletions, copy number changes, and some fusions, suitable for scenarios requiring comprehensive assessment.

Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC): mainly used to assist judgment at the level of gene rearrangement, amplification, or protein expression, often complementary to other methods.

Sample types and quality control

Sample types include paraffin-embedded tissue, fresh frozen tissue, cytology samples, and liquid biopsy samples such as blood. Different samples have different requirements for nucleic acid quality, tumor cell proportion, and fixation conditions. It is generally recommended to assess tumor cell content before testing and, when necessary, perform enrichment or microdissection to reduce interference from non-tumor nucleic acids. Laboratories should establish quality indicators for nucleic acid extraction, library construction, or amplification steps, such as common parameters including nucleic acid purity, fragment distribution, and library concentration.

Key points for platform selection and result reporting

Selecting a testing platform requires comprehensive consideration of clinical needs, sample accessibility, testing throughput, reporting cycle, and quality system. Report content should preferably include the testing method, testing scope, main variant results, and interpretive notes. For variants of uncertain significance, neutral expressions such as "variant of uncertain clinical significance" should be used to avoid overinterpretation. Testing institutions should also retain raw data and records of bioinformatics analysis workflows for traceability.

Technical limitations and reasonable expectations

Any testing method has certain limitations, such as PCR covering only preset sites, NGS possibly having uneven coverage of specific regions, and liquid biopsy possibly being affected by plasma cell-free nucleic acid concentration. Therefore, interpretation of results needs to be combined with the patient's clinical information, pathological diagnosis, and other auxiliary examinations, and should not be used alone as the sole basis for medication or prognosis judgment.

Development trends and selection recommendations

In the future, tumor gene mutation testing may develop toward greater automation, standardization, and multi-omics integration. When choosing upgrade pathways, laboratories should prioritize methodological stability, kit applicability, and data compatibility, and avoid blindly pursuing higher or lower parameters while neglecting actual clinical value.